Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Journal of Thrombosis and Thrombolysis
Erschienen in: Journal of Thrombosis and Thrombolysis 3/2013

01.04.2013

Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know

verfasst von: Rakhi P. Naik, Michael B. Streiff, Sophie Lanzkron

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Venous thromboembolism (VTE) is common in patients with sickle cell disease (SCD). The etiology of increased risk of VTE in SCD patients is multifactorial and is related to both traditional factors and SCD-specific factors. Traditional risk factors such as central venous catheters, frequent hospitalization, orthopedic surgeries for avascular necrosis, and pregnancy may lead to increased incidence of VTE in the SCD population. In addition, SCD itself appears to be a hypercoagulable state, and many SCD-specific factors such as thrombophilic defects, genotype and splenectomy may modify the risk of VTE. SCD complications such as acute chest syndrome and pulmonary hypertension may also be related to VTE. Anticoagulation experts should be aware of these factors to help inform prophylaxis and treatment decisions.
Literatur
1.
Bunn HF (1997) Pathogenesis and treatment of sickle cell disease. N Engl J Med 337(11):762–769PubMedCrossRef
2.
Famodu AA, Oduwa D (1995) Platelet count and platelet factor 3 (PF-3) availability in sickle cell disease. Br J Biomed Sci 52(4):323–324PubMed
3.
Foulon I, Bachir D, Galacteros F, Maclouf J (1993) Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619. Arterioscler thromb 13(3):421–426PubMedCrossRef
4.
Kenny MW, George AJ, Stuart J (1980) Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol 33(7):622–625PubMedCrossRef
5.
Westerman M, Pizzey A, Hirschman J et al (2008) Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 142(1):126–135PubMedCrossRef
6.
Westerman MP, Green D, Gilman-Sachs A et al (1999) Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med 134(4):352–362PubMedCrossRef
7.
Ataga KI, Orringer EP (2003) Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 115(9):721–728PubMedCrossRef
8.
Chiu D, Lubin B, Roelofsen B, van Deenen LL (1981) Sickled erythrocytes accelerate clotting in vitro: an effect of abnormal membrane lipid asymmetry. Blood 58(2):398–401PubMed
9.
Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ (2007) Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 110(6):2166–2172PubMedCrossRef
10.
Ataga KI (2009) Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica 94(11):1481–1484PubMedCrossRef
11.
12.
Novelli EM, Huynh C, Gladwin MT, Moore CG, Ragni MV (2012) Pulmonary embolism in sickle cell disease: a case-control study. J Thromb Haemost 10:760–766PubMedCrossRef
13.
Stein PD, Beemath A, Meyers FA, Skaf E, Olson RE (2006) Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med 119(10):897.e7–897.e11CrossRef
14.
Lijfering WM, Brouwer JL, Veeger NJ et al (2009) Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2,479 relatives. Blood 113(21):5314–5322PubMedCrossRef
15.
Jeng MR, Feusner J, Skibola C, Vichinsky E (2002) Central venous catheter complications in sickle cell disease. Am J Hematol 69(2):103–108PubMedCrossRef
16.
Abdul-Rauf A, Gauderer M, Chiarucci K, Berman B (1995) Long-term central venous access in patients with sickle cell disease. incidence of thrombotic and infectious complications. J Pediatr Hematol Oncol 17(4):342–345PubMedCrossRef
17.
Alkindi S, Matwani S, Al-Maawali A, Al-Maskari B, Pathare A (2012) Complications of PORT-A-CATH((R)) in patients with sickle cell disease. J Infect Public Health 5(1):57–62PubMedCrossRef
18.
Raj A, Bertolone S, Bond S, Burnett D, Denker A (2005) Cathlink 20: a subcutaneous implanted central venous access device used in children with sickle cell disease on long-term erythrocytapheresis–a report of low complication rates. Pediatr Blood Cancer 44(7):669–672PubMedCrossRef
19.
Phillips G, Slingluff C, Hartman J, Thomas P, Akwari O (1988) Totally implantable intravenous catheters in the management of sickle cell anemia. Am J Hematol 29(3):134–138PubMedCrossRef
20.
Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21(19):3665–3675PubMedCrossRef
21.
Takemoto CM (2012) Venous thromboembolism in cystic fibrosis. Pediatr Pulmonol 47(2):105–112PubMedCrossRef
22.
Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA (2010) Acute care utilization and rehospitalizations for sickle cell disease. JAMA 303(13):1288–1294PubMedCrossRef
23.
Epstein K, Yuen E, Riggio JM, Ballas SK, Moleski SM (2006) Utilization of the office, hospital and emergency department for adult sickle cell patients: a five-year study. J Natl Med Assoc 98(7):1109–1113PubMed
24.
Gardner K, Bell C, Bartram JL et al (2010) Outcome of adults with sickle cell disease admitted to critical care - experience of a single institution in the UK. Br J Haematol 150(5):610–613PubMedCrossRef
25.
Vichinsky EP, Neumayr LD, Earles AN et al (2000) Causes and outcomes of the acute chest syndrome in sickle cell disease. national acute chest syndrome study group. N Engl J Med 342(25):1855–1865PubMedCrossRef
26.
Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C (2005) Outcome of sickle cell anemia: a 4-decade observational study of 1,056 patients. Medicine (Baltimore) 84(6):363–376CrossRef
27.
Vichinsky EP, Neumayr LD, Haberkern C et al (1999) The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the national sickle cell surgery study group. Am J Hematol 62(3):129–138PubMedCrossRef
28.
Adam S, Jonassaint J, Kruger H et al (2008) Surgical and obstetric outcomes in adults with sickle cell disease. Am J Med 121(10):916–921PubMedCrossRef
29.
Villers MS, Jamison MG, De Castro LM, James AH (2008) Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol 199(2):125.e1–125.e5CrossRef
30.
James AH, Jamison MG, Brancazio LR, Myers ER (2006) Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 194(5):1311–1315PubMedCrossRef
31.
Kucuk O, Gilman-Sachs A, Beaman K, Lis LJ, Westerman MP (1993) Antiphospholipid antibodies in sickle cell disease. Am J Hematol 42(4):380–383PubMedCrossRef
32.
Olayemi EE, Bazuaye GN (2009) Lupus anticoagulant and leg ulcers in sickle cell anemia. Indian J Dermatol 54(3):251–254PubMedCrossRef
33.
Schnog JB (2004) Mac Gillavry MR, van Zanten AP, et al. Protein C and S and inflammation in sickle cell disease. Am J Hematol 76(1):26–32PubMedCrossRef
34.
Piccin A, Murphy C, Eakins E et al (2012) Protein C and free protein S in children with sickle cell anemia. Ann Hematol 91(10):1669–1671PubMedCrossRef
35.
Tam DA (1997) Protein C and protein S activity in sickle cell disease and stroke. J Child Neurol 12(1):19–21PubMedCrossRef
36.
Khanduri U, Gravell D, Christie BS, Al Lamki Z, Zachariah M, Cherian E (1998) Reduced protein C levels—a contributory factor for stroke in sickle cell disease. Thromb Haemost 79(4):879–880PubMed
37.
Porter JB, Young L, Mackie IJ, Marshall L, Machin SJ (1993) Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II. Br J Haematol 83(3):459–465PubMedCrossRef
38.
Taher A, Isma’eel H, Mehio G et al (2006) Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the mediterranean area and iran. Thromb Haemost 96(4):488–491PubMed
39.
Schilling RF, Gangnon RE, Traver MI (2008) Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost 6(8):1289–1295PubMedCrossRef
40.
Cappellini MD (2007) Coagulation in the pathophysiology of hemolytic anemias. Hematol Am Soc Hematol Educ Program 2007:74–78CrossRef
41.
Taher AT, Musallam KM, Karimi M et al (2010) Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the optimal care study. Blood 115(10):1886–1892PubMedCrossRef
42.
Rogers ZR, Wang WC, Luo Z et al (2011) Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the baby hug trial. Blood 117(9):2614–2617PubMedCrossRef
43.
Lane PA, O’Connell JL, Lear JL et al (1995) Functional asplenia in hemoglobin SC disease. Blood 85(8):2238–2244PubMed
44.
Kato GJ, Gladwin MT, Steinberg MH (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 21(1):37–47PubMedCrossRef
45.
Ballas SK, Lewis CN, Noone AM, Krasnow SH, Kamarulzaman E, Burka ER (1982) Clinical, hematological, and biochemical features of hb SC disease. Am J Hematol 13(1):37–51PubMedCrossRef
46.
Manci EA, Culberson DE, Yang YM et al (2003) Causes of death in sickle cell disease: an autopsy study. Br J Haematol 123(2):359–365PubMedCrossRef
47.
Mekontso Dessap A, Deux JF, Abidi N et al (2011) Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 184(9):1022–1029PubMedCrossRef
48.
Miller ST (2011) How I treat acute chest syndrome in children with sickle cell disease. Blood 117(20):5297–5305PubMedCrossRef
49.
Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ (2012) Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA 307(12):1254–1256PubMedCrossRef
50.
Anthi A, Machado RF, Jison ML et al (2007) Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med 175(12):1272–1279PubMedCrossRef
51.
Adedeji MO, Cespedes J, Allen K, Subramony C, Hughson MD (2001) Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 125(11):1436–1441PubMed
52.
Jerath A, Murphy P, Madonik M, Barth D, Granton J, de Perrot M (2011) Pulmonary endarterectomy in sickle cell haemoglobin C disease. Eur Respir J 38(3):735–737PubMedCrossRef
53.
Haque AK, Gokhale S, Rampy BA, Adegboyega P, Duarte A, Saldana MJ (2002) Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 33(10):1037–1043PubMedCrossRef
54.
Ataga KI, Moore CG, Hillery CA et al (2008) Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 93(1):20–26PubMedCrossRef
55.
Ataga KI, Key NS (2007) Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematol Am Soc Hematol Educ Program 2007:91–96
56.
Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494SPubMedCrossRef
57.
Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P (2011) Clinical guidelines committee of the American college of physicians. venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the american college of physicians. Ann Intern Med 155(9):625–632PubMed
58.
Falck-Ytter Y, Francis CW, Johanson NA et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e278S–e325SPubMedCrossRef
59.
Bates SM (2011) Pregnancy-associated venous thromboembolism: prevention and treatment. Semin Hematol 48(4):271–284PubMedCrossRef
60.
Naik RP, Lanzkron S (2012) Baby on board: what you need to know about pregnancy in the hemoglobinopathies. Hematol Am Soc Hematol Educ Program 2012:208–214
61.
Kabrhel C, Mark Courtney D, Camargo CA et al (2010) Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med 17(6):589–597PubMedCrossRef
62.
Colella MP, De Paula EV, Conran N et al (2012) Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia. J Thromb Haemost 10(9):1967–1970PubMedCrossRef
Metadaten
Titel
Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know
verfasst von
Rakhi P. Naik
Michael B. Streiff
Sophie Lanzkron
Publikationsdatum
01.04.2013
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 3/2013
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-013-0895-y

Weitere Artikel der Ausgabe 3/2013

Journal of Thrombosis and Thrombolysis 3/2013 Zur Ausgabe

OriginalPaper

Monitoring target specific anticoagulants

OriginalPaper

Patients with stable, therapeutic INR values should remain on warfarin

CME/CNE Article

Impact of target-specific oral anticoagulants on transitions of care and outpatient care models

OriginalPaper

Top practice-changing articles over the last two years

OriginalPaper

Rationale supporting an “opt-out” policy for pharmacological venous thromboembolism prophylaxis in hospitalized medical patients

CME/CNE Article

Assessing bleeding risk in patients taking anticoagulants

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise